The Salvage Therapy in Lung Adenocarcinoma Initially Harbored Susceptible EGFR Mutation and Acquired Resistance Occurred to the First-line Gefitinib and Second-line Cytotoxic Chemotherapy
作者单位：Department of Internal MedicineKaohsiung Municipal Ta-Tung HospitalKaohsiung Medical University Division of Pulmonary and Critical Care Medicine Kaohsiung Medical University HospitalKaohsiung Medical University Faculty of MedicineCollege of MedicineKaohsiung Medical University Graduate Institute of MedicineCollege of MedicineKaohsiung Medical University Division of Chest SurgeryDepartment of SurgeryKaohsiung Medical University HospitalKaohsiung Medical University Division of Hematology and OncologyDepartment of Internal MedicineKaohsiung Medical University HospitalKaohsiung Medical University Department of Medical ImagingKaohsiung Medical University HospitalKaohsiung Medical University
会议名称：《第九届中国肿瘤学术大会暨第十五届海峡两岸肿瘤学术大会》
会议日期：2016年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
摘 要：正Background:Epidermal growth factor receptor-tyrosine kinase inhibitor（EGFR-TKI）,such as gefitinib,could provide better efficacy and prolonged progress free survival（PFS）than cytotoxic chemotherapy for metastatic lung non-squamous cell carcinoma harboring susceptible EGFR mutation when it was served as the first line ***,the cytotoxic chemotherapy was regarded as the standard second-line and third-line therapy to
